Zymeworks

Zymeworks ROCE

The Return on Capital Employed (ROCE) of Zymeworks (ZYME) as of Oct 24, 2026 is -34.46 %. In the previous year, Return on Capital Employed (ROCE) was -40.47 % — a change of -14.85% (higher).

ROCE

-34.46 %

YoY

-14.85%

Last updated:

In 2025, Zymeworks's return on capital employed (ROCE) was -34.46 %, a -14.85% increase from the -40.47 % ROCE in the previous year.

The Zymeworks ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-18.35 USD
Jan 1, 2019
-61.58 USD
Jan 1, 2020
-45.73 USD
Jan 1, 2021
-86.57 USD
Jan 1, 2022
26.48 USD
Jan 1, 2023
-29.70 USD
Jan 1, 2024
-40.47 USD
Jan 1, 2025
-34.46 USD
The Zymeworks ROCE history
YEARROCEYoY
-34.46 %-14.85%
-40.47 %+36.27%
-29.70 %-212.17%
26.48 %-130.59%
-86.57 %+89.29%
-45.73 %-25.74%
-61.58 %+235.54%
-18.35 %+117.76%
-8.43 %-98.02%
-424.82 %+288.19%
-109.44 %+241.46%
-32.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zymeworks Stock analysis

What does Zymeworks do? Zymeworks, Inc. generates revenue through its clinical-stage biopharmaceutical products and platforms. The company develops biotherapeutics using its Azymetric bispecific platform, which creates antibodies binding multiple targets, and its ZymeLink ADC platform, combining cytotoxins with tumor-targeting antibodies. Lead product ZW25 targets HER2 for cancer treatment, while ZW49 integrates ZW25 design with ZymeLink for enhanced therapy. These products are developed for clinical trials and potential commercialization, with revenue expected from future partnerships or sales once approved. Zymeworks focuses on oncology and immune modulation, leveraging its EFECT platform for immune cell recruitment control. The company’s platforms and product candidates are designed for pharmaceutical partnerships, with potential buyers including biopharmaceutical firms seeking innovative cancer therapies. Revenue streams will emerge from licensing agreements, milestone payments, and future product sales once clinical development progresses. The company’s product pipeline includes ZW25 and ZW49, both targeting HER2-related cancers. ZW25 uses Azymetric technology, while ZW49 incorporates ZymeLink for antibody-drug conjugates. These are developed for potential commercialization, with revenue anticipated from biopharmaceutical partners who license these technologies or products for further development and marketing. Zymeworks is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Zymeworks's Return on Capital Employed (ROCE)

Zymeworks's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Zymeworks's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Zymeworks's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Zymeworks’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Zymeworks stock

Return on Capital Employed (ROCE) of Zymeworks is -34.46 % in 2025.

Return on Capital Employed (ROCE) of Zymeworks changed from -40.47 % to -34.46 %, representing a -14.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Zymeworks since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Zymeworks with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Zymeworks

All Key Metrics — Zymeworks